Skip to main content

Advertisement

Table 3 Trends in the prescription of antibacterial compounds and for the main resistance phenotypes

From: Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis

  Gradient per quarter Gradient (95% CI) R 2 p value Trend
Penicilins* 14.61 (0.85; 28.26) 0.529 0.041
Piperacillin + tazobactam* 10.91 (3.74; 18.08) 0.698 0.010
Ampicillin + enzyme inhibitor 3.27 (− 11.14; 17.67) 0.049 0.599
Amoxicillin + enzyme inhibitor 0.34 (− 1.72; 2.39) 0.026 0.702
Cephalosporins − 15.95 (− 34.73; 2.82) 0.419 0.083
Ceftriaxone* − 28.23 (− 47.55; − 8.91) 0.681 0.012
Cefuroxime 3.48 (− 5.60; 12.56) 0.128 0.385
Carbapenems* 13.12 (0.48; 25.75) 0.518 0.044
Imipenem + enzyme inhibitor 1.55 (− 4.57; 7.68) 0.060 0.558
Meropenem* 14.63 (6.25; 23.00) 0.753 0.005
Ertapenem − 3.06 (− 8.76; 2.63) 0.224 0.237
Fluoroquinolones − 0.60 (− 7.81; 6.60) 0.007 0.844
Aminoglycosides 1.74 (− 1.96; 5.44) 0.180 0.294
Other* 27.90 (10.37; 45.44) 0.717 0.008
MRSA 0.10 (− 0.96; 1.16) 0.009 0.824
ESBL E. coli 0.12 (− 0.08; 0.33) 0.261 0.196
ESBL K. pneumoniae − 0.08 (− 1.05; 0.90) 0.006 0.850
ESBL P. mirabilis − 0.15 (− 0.66; 0.37) 0.074 0.515
Combined-resistant P. aeruginosa* 0.78 (0.27; 1.28) 0.707 0.009
Carbapenem-resistant Ps. aeruginosa* 0.74 (0.21; 1.27) 0.666 0.013
Carbapenem-resistant A. baumannii − 0.10 (− 0.59; 3.99) 0.039 0.641
  1. * Results where R2 > 0.3 and p ≤ 0.05